Internal Medicine, Critical Care Medicine · New York, NY
NPI
1760709265
Since 2010
Specialty
Internal Medicine, Critical Care Medicine
Code 207RC0200X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
196 Canal St, 5th Floor
New York, NY, 10013
Phone (646) 441-1545
Groups this clinician bills Medicare through
Medicare paid, 2024
$45K
1,131 services
Medicare patients, 2024
86
Average age 76
Drug cost, 2024
$4.8M
12,059 prescriptions
Company payments, 2025
$4,154
From 11 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Singwu D Law was code 94664 (e&m - miscellaneous), 337 times for 83 patients. In total Singwu D Law billed 1,131 services in 18 codes, and Medicare paid $45K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2019-03-28.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 94664 E&M - Miscellaneous | Office | 337 | 83 | $15.73 | $5,302 |
| 99213 Office E&M - Established | Office | 311 | 75 | $75.66 | $24K |
| 94060 Pulmonary Function Testing | Office | 97 | 74 | $32.47 | $3,149 |
| 99214 Office E&M - Established | Office | 58 | 35 | $97.39 | $5,648 |
| 36415 Venipuncture Blood Collection | Office | 29 | 21 | $8.65 | $251 |
| 89220 Test - Miscellaneous | Office | 28 | 12 | $17.74 | $497 |
| 99204 Office E&M - New | Office | 24 | 24 | $143.31 | $3,440 |
By year: 2022 $44K for 1,080 services; 2023 $43K for 1,063 services; 2024 $45K for 1,131 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 29 | 21 | $8.65 | $251 |
Medicare prescription drug claims, 2024
In 2024, the drug Singwu D Law prescribed most often to Medicare patients was Trelegy Ellipta (Fluticasone/Umeclidin/Vilanter), with 1,657 prescriptions and refills. In total Singwu D Law wrote 12,059 Medicare prescriptions that cost $4.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 1,657 | 1,735 | 238 | $1.1M |
| Levocetirizine Dihydrochloride Generic | 1,275 | 1,322 | 269 | $4,657 |
| Stiolto Respimat Tiotropium Br/Olodaterol Hcl | 1,252 | 1,294 | 193 | $622K |
| Anoro Ellipta Umeclidinium Brm/Vilanterol Tr | 1,122 | 1,162 | 182 | $527K |
| Breztri Aerosphere Budesonide/Glycopyr/Formoterol | 817 | 863 | 130 | $548K |
| Montelukast Sodium Generic | 694 | 803 | 106 | $2,964 |
| Albuterol Sulfate Hfa Albuterol Sulfate | 674 | 881 | 201 | $16K |
| Isoniazid Generic | 307 | 360 | 73 | $2,099 |
| Breo Ellipta Fluticasone/Vilanterol | 226 | 240 | 37 | $95K |
| Fluticasone Propionate Generic | 216 | 216 | 70 | $2,182 |
| Xolair Omalizumab | 193 | 193 | 23 | $801K |
| Atorvastatin Calcium Generic | 180 | 221 | 28 | $695 |
| Clarithromycin Generic | 165 | 195 | 27 | $3,052 |
| Rifampin Generic | 161 | 196 | 33 | $4,962 |
| Azelastine Hcl Generic | 155 | 174 | 51 | $3,641 |
Brand drugs: 6,290 claims; generic drugs: 5,755 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Singwu D Law $4,154 ($4,154 in general payments such as food, travel and fees) from 11 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $1,748.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 58 | $1,748 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 23 | $714 |
| GlaxoSmithKline, LLC. GSK | 43 | $702 |
| Philips North America LLC PHG | 11 | $270 |
| Insmed, Inc. INSM | 14 | $180 |
| Genentech USA, Inc. ROG.SW | 10 | $164 |
| Electromed, Inc. ELMD | 12 | $143 |
| Amgen Inc. AMGN | 3 | $82.4 |
| Regeneron Healthcare Solutions, Inc. REGN | 3 | $74.28 |
| Lilly USA, LLC LLY | 3 | $61.1 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.